Guan Fang-Shu, He Dong-Hua, Li Yi, Zhang Yi, Zheng Gao-Feng, Zhu Yuan-Yuan, He Jing-Song, Zhang En-Fan, Cai Zhen, Zhao Yi
Bone Marrow Transplantation Center, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China.
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Aug;31(4):1056-1060. doi: 10.19746/j.cnki.issn.1009-2137.2023.04.020.
To investigate the efficacy and safety of plerixafor combined with granulocyte colony-stimulating factor (G-CSF) in mobilizing peripheral blood hematopoietic stem cells in patients with lymphoma.
The clinical data of lymphoma patients who received autologous hematopoietic stem cell mobilization using plerixafor combined with G-CSF from January 2019 to December 2021 were retrospectively analyzed. The patients received 3 kinds of mobilization regimens: front-line steady-state mobilization, preemptive intervention, and recuse mobilization. The acquisition success rate, excellent rate of collection, and incidence of treatment-related adverse reaction were counted. The influence of sex, age, disease remission status, bone marrow involvement at diagnosis, chemotherapy lines, number of chemotherapy, platelet count and number of CD34 cells on the day before acquisition in peripheral blood on the collection results were analyzed to identify the risk factors associated with poor stem cell collection.
A total of 43 patients with lymphoma were enrolled, including 7 cases who received front-line steady-state mobilization, 19 cases who received preemptive intervention, and 17 cases who received recuse mobilization. The overall acquisition success rate was 58.1% (25/43) after use of plerixafor combined with G-CSF, and acquisition success rate of front-line steady-state mobilization, preemptive intervention, and recuse mobilization was 100%, 57.9%(11/19), and 41.2%(7/17), respectively. The excellent rate of collection was 18.6%(8/43). A total of 15 patients experienced mild to moderate treatment-related adverse reactions. The number of CD34 cells < 5 cells/μl in peripheral blood on the day before collection was an independent risk factor affecting stem cell collection.
Plerixafor combined with G-CSF is a safe and effective mobilization regimen for patients with lymphoma. The number of CD34 cells in peripheral blood on the day before collection is an predictable index for the evaluation of stem cell collection.
探讨普乐沙福联合粒细胞集落刺激因子（G-CSF）动员淋巴瘤患者外周血造血干细胞的疗效及安全性。
回顾性分析2019年1月至2021年12月期间接受普乐沙福联合G-CSF进行自体造血干细胞动员的淋巴瘤患者的临床资料。患者接受3种动员方案：一线稳态动员、抢先干预和挽救动员。统计采集成功率、采集优良率及治疗相关不良反应发生率。分析性别、年龄、疾病缓解状态、诊断时骨髓受累情况、化疗线数、化疗次数、采集前一天外周血血小板计数及CD34细胞数量对采集结果的影响，以确定与干细胞采集不佳相关的危险因素。
共纳入43例淋巴瘤患者，其中7例接受一线稳态动员，19例接受抢先干预，17例接受挽救动员。使用普乐沙福联合G-CSF后总体采集成功率为58.1%（(25/43)），一线稳态动员、抢先干预和挽救动员的采集成功率分别为100%、57.9%（(11/19)）和41.2%（(7/17)）。采集优良率为18.6%（(8/43)）。共有15例患者发生轻至中度治疗相关不良反应。采集前一天外周血CD34细胞数<5个/μl是影响干细胞采集的独立危险因素。
普乐沙福联合G-CSF对淋巴瘤患者是一种安全有效的动员方案。采集前一天外周血CD34细胞数量是评估干细胞采集的一个可预测指标。
